piracetam has been researched along with Developmental Disabilities in 4 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the relationship between behavioral problems, location of electroencephalogram (EEG) paroxysmal abnormalities (PA), and treatment with levetiracetam in children with pervasive developmental disorder (PDD) and epilepsy." | 7.80 | Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy. ( Aihara, M; Kanemura, H; Ohyama, T; Sano, F; Sugita, K, 2014) |
| "Synaptic vesicle protein 2A (SV2a) is the binding site of the antiepileptic drug levetiracetam and the only known synaptic vesicle target of an epilepsy medication." | 3.81 | Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation. ( Huq, AM; Serajee, FJ, 2015) |
| "We investigated the relationship between behavioral problems, location of electroencephalogram (EEG) paroxysmal abnormalities (PA), and treatment with levetiracetam in children with pervasive developmental disorder (PDD) and epilepsy." | 3.80 | Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy. ( Aihara, M; Kanemura, H; Ohyama, T; Sano, F; Sugita, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanemura, H | 1 |
| Sano, F | 1 |
| Ohyama, T | 1 |
| Sugita, K | 1 |
| Aihara, M | 1 |
| Serajee, FJ | 1 |
| Huq, AM | 1 |
| Duane, DD | 1 |
| Tureci, E | 1 |
| Asan, Z | 1 |
| Eser, M | 1 |
| Tanriverdi, T | 1 |
| Alkan, F | 1 |
| Erdincler, P | 1 |
4 other studies available for piracetam and Developmental Disabilities
| Article | Year |
|---|---|
Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy.
Topics: Adolescent; Anticonvulsants; Behavioral Symptoms; Brain Waves; Child; Developmental Disabilities; El | 2014 |
Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
Topics: Anticonvulsants; Child, Preschool; Developmental Disabilities; Dyskinesias; Epilepsy; Female; Growth | 2015 |
Correspondence on ''the unrecognized epilepsy spectrum: the effects of levetiracetam on neuropsychological functioning in relation to subclinical spike production''.
Topics: Anticonvulsants; Brain; Child; Cognition; Cognition Disorders; Developmental Disabilities; Electroen | 2009 |
The effects of valproic acid and levetiracetam on chicken embryos.
Topics: Animals; Anticonvulsants; Chick Embryo; Developmental Disabilities; Dose-Response Relationship, Drug | 2011 |